Kashyap Patel, MD, discusses the goals of the Community Oncology Alliance (COA) in forming its biosimilars committee.
Biosimilars are a totally new class of drug in the United States, and unlike generics, there's a complex science involved in developing biosimilars.
But there’s a tremendous knowledge gap between the providers. Multiple studies have shown that between 1 and 4 to 1 and 2 doctors are not familiar with the FDA pathway, which is 351(k) for the biosimilar.
So [the Community Oncology Alliance, COA] plays a central role in evaluating this knowledge gap and bridging that gap by bringing the evidence-based scientific education piece to all the stakeholders, which includes in patients, physicians, as well as providers.